Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Biological: CMV-Peptide-Specific T cells

First Posted Date: 2008-05-08

Last Posted Date: 2020-03-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00674648

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Phase 1

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Radiation: 131 I-iodine (131-I), 124 I-iodine (124-I)

First Posted Date: 2008-05-07

Last Posted Date: 2025-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT00673010

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

First Posted Date: 2008-05-06

Last Posted Date: 2015-02-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT00672165

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

Phase 1

Completed

Conditions: Renal Cancer
Kidney Cancer

Interventions: Drug: Ultrasound with intravenous microbubble contrast injection

First Posted Date: 2008-05-05

Last Posted Date: 2015-12-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT00671411

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma
Hodgkin's Disease

Interventions: Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim

First Posted Date: 2008-04-28

Last Posted Date: 2018-01-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00667615

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Phelps, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ BaskingRidge, Basking Ridge, New Jersey, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

and more 2 locations

Development of a Clinical Trial Specific Question Prompt List

Completed

Conditions: Breast Cancer
Lung Cancer
Prostate Cancer

Interventions: Behavioral: focus groups

First Posted Date: 2008-04-21

Last Posted Date: 2013-05-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 67

Registration Number: NCT00662324

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Squamous Cell Cancer
Head and Neck

Interventions: Biological: cetuximab

First Posted Date: 2008-04-18

Last Posted Date: 2018-01-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00661427

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 14 locations

Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

Not Applicable

Completed

Conditions: Beta Thalassemia Major
Congenital Anemias

Interventions: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)

First Posted Date: 2008-04-15

Last Posted Date: 2016-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT00658385

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Procedure: PET scan with injection of 5-8 mCi of 18FES

First Posted Date: 2008-04-01

Last Posted Date: 2015-08-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT00647790

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

Not Applicable

Completed

Conditions: Hodgkin's Disease
Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma

Interventions: Drug: Rituximab

First Posted Date: 2008-04-01

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT00648037

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy